Ibrutinib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<scene name='99/997914/Overall/1'>Tyrosine-protein kinase BTK with Ibrutinib</scene> ([[5p9j]]). | <scene name='99/997914/Overall/1'>Tyrosine-protein kinase BTK with Ibrutinib</scene> ([[5p9j]]). | ||
<scene name='99/997914/Binding_site/2'>Ibrutinib binding site</scene>. Water molecules are shown as red spheres. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 17:34, 5 October 2023
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.[1][2] See also Ibrutinib. (5p9j). . Water molecules are shown as red spheres.
|
| ||||||||||
ReferencesReferences
- ↑ "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Retrieved 21 April 2020.
- ↑ "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Retrieved 14 July 2021.